CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trialBusiness Wire • 05/02/24
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolioBusiness Wire • 05/01/24
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'Market Watch • 04/30/24
'A shadow of what I was': Dad who suffered brain injury days after getting COVID jab sues AstraZenecaSkynews • 04/29/24
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralowBusiness Wire • 04/29/24
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 TrialBusiness Wire • 04/29/24
BHP, Anglo American, Meta, Google, Microsoft, AstraZeneca, Rubrik, ComCast and more - Markets DefusedProactive Investors • 04/27/24
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 04/25/24
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers LagsInvestors Business Daily • 04/25/24